Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
-
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
-
Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spero shares of...
-
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
-
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
-
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
-
Event is taking place on Thursday, October 6th at 11:30 a.m. ET Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical...
-
The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential...
-
CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO). “Kamal...
-
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...